Highest-materiality recent filing
iSpecimen flagged for Nasdaq equity shortfall; equity $814K vs $2.5M minimum
Received Nasdaq notice on May 29, 2026 for non-compliance with minimum stockholders' equity of $2.5M; equity was $814,038.
iSpecimen prices $2.5M private placement at $5.12/share; regains Nasdaq minimum bid price compliance
Private placement of 488,281 shares and pre-funded warrants for gross proceeds of ~$2.5M at $5.12 per share (or $5.1199 for warrants).
iSpecimen effectuates 1-for-40 reverse stock split to regain Nasdaq compliance
Reverse stock split effective 4:30 p.m. ET on April 27, 2026; trading on split-adjusted basis began April 28.
iSpecimen raises $5.5M via Series C Convertible Preferred Stock at $800/share
Issued 6,875 shares of Series C Convertible Non-Voting Preferred at $800/share for $5.5M aggregate.
iSpecimen receives Nasdaq deficiency notice for bid price below $1.00; cure deadline May 18, 2026
Notice received Nov 19, 2025; stock continues trading under ISPC with no immediate delisting.
Reverse stock split approved at ratio from 1:10 to 1:100; Board to set exact ratio.
iSpecimen plans $200M Solana-based digital asset treasury, hires BlockArrow
iSpecimen to build up to $200M corporate treasury reserve on Solana blockchain ecosystem.
iSpecimen raises $1.75M in private placement of common stock and pre-funded warrants
Gross proceeds ~$1.75M from 1,559,828 shares (or pre-funded warrants) at $1.122/share; closed August 4, 2025.
iSpecimen closes $4M public offering of common stock and pre-funded warrants
Sold 5,714,283 securities (1,482,644 shares + 4,231,639 pre-funded warrants) at $0.70/share for gross $4M.
Received Nasdaq letter on June 4, 2025 regarding non-compliance with Listing Rule 5550(b)(1) requiring minimum $2.5M stockholders' equity.
iSpecimen auditor Wolf & Company resigns; Bush & Associates appointed as new independent auditor
Wolf & Company resigned as iSpecimen's auditor effective March 7, 2025.
iSpecimen names Yuying Liang CFO, unveils plan to expand cancer biospecimen procurement
Appointed Yuying Liang as CFO effective Dec 13, 2024; monthly fee of $25k under engagement with his professional corp.
iSpecimen CEO/CFO/Treasurer Tracy Curley departs amid dispute with board over company direction
Tracy Curley's employment as CEO, CFO, and Treasurer ended Nov 8, 2024; parties dispute resignation vs termination.
iSpecimen raises ~$5M in public offering of stock and warrants; signs $2M IR agreement
Offering of 132,814 common shares and pre-funded warrants for up to 1,533,852 shares at $3.00 per share, grossing $4,998,464.
iSpecimen ex-CIO files arbitration claim for $586,800; company defends
Benjamin Bielak, former CIO, resigned July 14, 2024, and filed arbitration claim for unpaid bonuses/severance totaling $586,800 plus fees/interest.
iSpecimen closes $1M note at 18% interest; lender secures three board seats
Issued $1M senior note with 18% annual interest, maturing in 12 months; net proceeds $960,000 after $40,000 placement fee.
iSpecimen to effect 1-for-20 reverse stock split on Sep 13, 2024
Reverse split ratio 1:20, effective 4:30 p.m. ET Sep 13; trading on split-adjusted basis begins Sep 16.
iSpecimen Q2 revenue up 76% to $2.86M; net loss narrows to $2.11M
Revenue $2.86M (+76% YoY); net loss $2.11M ($0.19/sh) vs $3.5M loss ($0.39/sh) in Q2 2023.
iSpecimen stockholders authorize reverse split; director Ross resigns
Director Andrew L. Ross resigns effective July 25, 2024; no disagreement with management.
iSpecimen Q1 revenue down 22% to $2.29M; net loss widens to ($0.32)/share
Revenue $2.29M vs $2.95M YoY; specimen count fell 39% to 5,241, offset by 28% higher ASP ($437).
iSpecimen receives Nasdaq extension to Oct 7, 2024 to regain $1 minimum bid price compliance
Received Nasdaq second 180-day compliance period through Oct 7, 2024 for minimum bid price.
iSpecimen FY2023 revenue $9.93M (-4.5% YoY), net loss $11.1M; cash burn improves to $657K in Q4
Revenue $9.93M vs $10.40M in 2022; specimen count fell 11% to 24,565 but ASP rose 7% to $404.
On June 20, 2025, the Board appointed Mr. Anthony Lau as a member of the Board, effective immediately, to fill one of the resulting vacancies.
On June 18, 2025, Richard J. Paolone and John L. Brooks III each resigned from the Board of Directors (the “Board”) of iSpecimen Inc. (the “Company”), effective immediately.
On June 18, 2025, Richard J. Paolone and John L. Brooks III each resigned from the Board of Directors (the “Board”) of iSpecimen Inc. (the “Company”), effective immediately.
Additionally, the Board appointed Mr. Richard Paolone as Chair of the Board, replacing Ms. Field in this role.
Ms. Siyun Yang was appointed as an independent director to fill the resulting vacancy, effective immediately.
On February 19, 2025, the Board of Directors (the “Board”) of iSpecimen Inc. (the “Company”) appointed Ms. Katharyn Field as President of the Company, effective immediately. In connection with her appointment, Ms. Field resigned as a member of the Board
On November 8, 2024, iSpecimen Inc. (the “Company”) and Tracy Curley mutually agreed to end Ms. Curley’s employment as Chief Executive Officer, Chief Financial Officer and Treasurer of the Company.
Ms. Curley resigned as a member of the Board of Directors (the “Board”), due to differences between Ms. Curley and the Board regarding the future direction of the Company.
The Company received letters of resignation from each of Steven Gullans and Theresa Mock, each as a member of the Board
effective upon Closing on September 25, 2024, Richard Paolone, Avtar Dhaliwal and Katherine (Katie) Field were each appointed to serve on the Board as a Class I director, a Class II director and a Class III director of the Company, respectively, with Ms. Field appointed as the chairperson of the Board
Elizabeth A. Graham, as a member and the chairperson of the Board, effective upon Closing
The Company received letters of resignation from each of Steven Gullans and Theresa Mock, each as a member of the Board
Max materiality 0.80 · Median 0.55 · Most common event other_material